Gapping up
In reaction to strong earnings/guidance:
- CVRS +21.2%, HZO +14.4%, ARAY +7.7%, TEL +5.3%, WKHS +5%, NVS +3.6%, TSS +2.5%, AUDC +2.5%, GE +1.9%, MBCN +1.2%, GD +1.2%, ROL +1.1%, NTRS +1%, SWK +0.5%, BHGE +0.5%
M&A news:
- MSCC +5.9% (report that the company is weighing its options after receiving an apparent takeover approach)
- TROX +0.9% (requests court to order FTC to defend its unmerited objection to the pro-competitive transaction of the titanium dioxide business of Cristal)
Other news:
- SPI +37% (signs strategic agreement with COOIX for blockchain business services)
- SRT +35.5% (StarTek and Amazon.com (AMZN) enter into Transaction Agreement under which the company agreed to issue to Amazon.com a warrant to acquire up to 4 mln shares of common stock), CERS +31.6% (Cerus reports its Phase 3 transfusion study of chronic anemia evaluating INTERCEPT-treated red blood cells in thalassemia patients met primary efficacy and safety endpoints), BAK +3.1% (issues statement, says it was not informed of any decision about the holding of a secondary share offering), OBLN +2.6% (modestly rebounding), NGD +1.8% (continued strength), RGNX +1.5% (REGENXBIO enters into strategic partnership with FUJIFILM Diosynth Biotechnologies), VTVT +1.4% (after closing near highs - up 28% on the day), STML +1.4% (prices 3.7 mln common stock offering at $14.00/share), VLO +1.3% (increases quarterly dividend by 14% to $0.80/share and approves incremental $2.5 bln share repurchase authorization), SIRI +1.1% ( affirms $0.011/share quarterly dividend, adds $2 bln to repurchase program), RARE +1.1% (prices offering of 4,385,965 shares of its common stock at $57.00 per share), .
Analyst comments:
- STO +2% (upgraded to Outperform from Underperform at Credit Suisse)
- AUO +1.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ANIK +1.5% (upgraded to Overweight at First Analysis Sec)
- WY +1.1% (upgraded to Buy from Neutral at BofA/Merrill)